fate therapeutics stock price target

Nasdaq AT CLOSE 400 PM EDT 031622. Fate Therapeutics stock price target raised to 88 from 55 at Wedbush Dec.

Fate Therapeutics Stock Falls On Trial Data For Lymphoma Treatment Thestreet

Analyst Recommendations on FATE THERAPEUTICS INC.

. Their forecasts range from 6000 to 14500. The average price target is 000 with a high estimate of 000 and a low estimate of 000. Find the latest Fate Therapeutics Inc.

The transaction was disclosed in a document filed with the SEC which can be accessed through this link. Fate Therapeutics Inc NASDAQFATE is active in pre-market trading today April 4 with shares climbing 407 from the last closing price. Ad Our Strong Buys Double the SP.

Morgan Stanley lowered their price target on shares of Fate Therapeutics from 7400 to 6200 and set an equal weight rating for the company in a research report on Wednesday December 15th. Fate Therapeutics Inc. Fate Therapeutics stock opened at 3305 on Friday.

AFTER HOURS 707 PM EDT 031622. The minimum target price for Fate Therapeutics analysts is 9858. FATE has a higher upside potential average analyst target price relative to current price than 100215 of stocks in the mid market cap category.

The average twelve-month price target for Fate Therapeutics is 9500 with a high price target of 14500 and a low price target of 6000. Today 200 Day Moving Average is the resistance level 6369. 7 2020 at 718 am.

9 brokerages have issued twelve-month target prices for Fate Therapeutics stock. 50 Day Moving Average is the resistance level 434. 6 hours agoFinally Wedbush upped their target price on shares of Fate Therapeutics from 7400 to 7700 and gave the company an outperform rating in a report on Tuesday March 1st.

Stock Price Forecast The 18 analysts offering 12-month price forecasts for Fate Therapeutics Inc have a median target of 9900 with a high estimate of 13500 and a low estimate of 4200. HC Wainwright Adjusts Fate Therapeutics Price Target to 115 from 122 Keeps Buy Rati. ET by Tomi Kilgore Fate Therapeutics stock price target raised to 65 from 40 at Truist.

Wedbush Adjusts Fate Therapeutics Price Target to 77 From 74 Keeps Outperform Ratin. Sign in to your SmartPortfolio to see more analyst recommendations. 69 rows Fate Therapeutics Stock Forecast NASDAQ.

According to MarketBeat the company currently has an average rating of Buy and an average target price of 9850. FATE analyst stock forecast price target and recommendation trends with in-depth analysis from research. The firm has a market cap of 316 billion a PE ratio of -1482 and a beta of 156.

Fate Therapeutics stock forecasts are adjusted once a day based on the closing price of the previous trading day. According to the issued ratings of 9 analysts in the last year the consensus rating for Fate Therapeutics stock is Buy based on the current 2 hold ratings and 7 buy ratings for FATE. Today 200 Day Moving Average is the resistance level 6452.

Fate Therapeutics stock forecasts are adjusted once a day based on the closing price of the previous trading day. Morgan Stanley Adjusts Fate Therapeutics Price Target to 52 From 62 Maintains Equalw. Stocks similar to Fate Therapeutics Inc in the Pharmaceutical.

FATE Price Target and. This suggests a possible upside of 1450 from the stocks current price. 50 Day Moving Average is the resistance level 4517.

NASDAQFATE - Get Rating General Counsel Cindy Tahl sold 25000 shares of the companys stock in a transaction that occurred on Friday April 1stThe stock was sold at an average price of 3885 for a total value of 97125000. On average they anticipate Fate Therapeutics stock price to reach 9500 in the next twelve months. Based On Fundamental Analysis.

5 Wall Street analysts that have issued a 1 year FATE price target the average FATE price target is 9360 with the highest FATE stock price forecast at 11500 and the lowest FATE stock price forecast at 7400. The minimum target price for Fate Therapeutics analysts is 9526. The stock is down 2938 year-to-date while moving 874.

1y Target Est 9453 Fair Value is the appropriate price for the shares of a company based on its earnings and growth rate also interpreted as when PE Ratio Growth Rate. In terms of how Fate Therapeutics Inc fares relative to Pharmaceutical Products stocks note that its average analyst price target is greater than 94038 of that group.

The Rally Likely To Continue For Fate Therapeutics After Positive Clinical Trials Data Nasdaq

Fate Therapeutics Nasdaq Fate Quotes And News Summary Benzinga